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EDITORIAL
Diagnosis of immunopathologic renal disease
The participation of immune processes in the pro-
duction of glomerular injury is generally accepted. The
ability of the immunopathologist to readily identify
and differentiate various immune pathways of injury
has provided much needed insight into the mechanisms
of glomerular injury and, in some cases, its etiology; it
also has the potential of leading to "immunospecific"
therapy. More and more, nephrology, transplantation
and pathology programs are realizing the importance
of immunopathologic classification of all renal disease.
This is reflected in the ever increasing demand for
immunopathologic services provided by groups like
our own (Table 1). In this editorial we will explore the
usefulness of some techniques available for detecting
immune glomerular and tubular injury and see how the
application of these techniques can help us identify,
understand and follow the immunopathologic pro-
cesses leading to renal damage.
In addition to antibody-initiated injury of the
glomerulus, the recent identification of "nonimmune"
complement (C) activation has caused considerable
speculation regarding the roles of the properdin
system, nephritic factors and microbial and parasitic
products in the production of hypocomplementemia
and glomerular injury mediated by mechanisms similar
to those operating in immune injury. Since this will be
the topic of a future editorial, this potential renal
damage mechanism will not be dealt with in depth
here.
Immunopathologic studies over the past 70 years,
first in animals and now in man, have convincingly
demonstrated two mechanisms by means of which
antibodies can induce glomerular injury. In one, anti-
bodies have specificity for antigens within the gb-
merular basement membrane (GBM) (so-called anti-
GBM antibodies). In the other, antibodies react with
circulating nonglomerular antigens and deposit pas-
sively as immune complexes in the glomerular filter.
Either type of glomerular antibody deposition can
result in tissue injury by bringing into play several
interrelated mediator systems, including the C cascade,
polymorphonuclear leukocytes and, potentially, such
things as kinins, vasoactive amines and coagulation
factors. These latter mediators may be of particular
importance in certain anti-GBM nephritis patients who
do not have glomerular C deposits (by immuno-
fluorescence) and in experimental acute serum sickness
in which C and polymorphonuclear leukocyte deple-
tion prevents vasculitis but not glomerulonephritis. In
addition to producing glomerular injury, antibodies
may also react either directly with tubular basement
membranes (TBM) in the form of anti-TBM anti-
bodies or deposit in the TBM, peritubular capillaries
and interstitium in the form of immune complexes,
thereby providing the phlogogenic stimulus which may
be responsible for the tubular and interstitial lesions
TabJe 1. Diagnostic renal immunofluorescence studieso
Renal specimens
submitted
per year
Glomerular immunofluorescent deposits
Immunoglobulin pattern, % Complement only
0/0
Negative
Linear Granular Indeterminant
1970
1971
1972
1973
Total
Mean
396
444
456
660
1956
7
5
4
4
5
49 5
48 6
48 2
50 1
49 3
8
6
12
11
9
31
35
34
34
34
Tissue for these studies was submitted by nephrology and transplantation groups throughout the United States.
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often observed in glomerulonephritis or interstitial
nephritis.
Since both major antibody-induced mechanisms of
glomerular damage can utilize similar mediators to
effect injury, it is not surprising that, in general,
routine clinical pathologic classifications are of little
help in their differentiation. To further complicate
matters, multiple histologic varieties of glomerular
injury and their attendant clinical courses may be
induced by a single immunologic stimulus in experi-
mental models of glomerulonephritis such as those
seen in chronic serum sickness in rabbits. A similar
variability in glomerular histologic response is ob-
served in the much more complicated immune com-
plex type of glomerular injury which accompanies
systemic lupus erythematosus (SLE). In this disease
individual differences in antigen-antibody systems
involved [1] might also contribute to the varied histo-
logic response.
No light or electron microscopic features are pathog-
nomonic of anti-GBM antibody-induced glomerular
injury. Immune complex deposits, however, should be
suspected in patients with increased mesangial regions
thought by many to represent increased phagocytic
activity. The subepithelial "spike" formation seen on
silver stain in patients with membranous glomerulo-
pathy results from extensions of basement membrane
material (argyrophilic) between subepithelial immune
complex deposits. At the electron microscopic level,
electron dense deposits, presumed and actually shown
to represent immune complex deposits, can be found
in and about the GBM. For example, isolated sub-
epithelial dense deposits or "humps" are seen fre-
quently in acute poststreptococcal glomerulone-
phropathy and generalized electron dense deposits
typify membranous glomerulopathy. In lupus nephri-
tis, electron dense deposits are also frequently found
in a subendothelial position, suggesting the particular
antigen-antibody system involved may result in
aggregates unable to pass through the GBM.
The availability of immunohistochemical methods
(fluorescent and enzymatic) for detecting deposition of
immunoglobulins (Ig) and other immunoreactive
proteins within renal tissue has provided a relatively
easy, available, and, we believe, necessary adjunct for
the routine study of renal disease. These studies may
be combined with elution of the antibodies [2] for in
vivo or in vitro specificity studies. In addition to anti-
bodies in glomerular deposits, circulating antibodies
reactive with the GBM or nonglomerular antigens may
be found. Evidence of cellular sensitivity can be
sought and renal antigens in the urine detected, in-
cluding those cross-reactive with the GBM. Growing
interest in the possible role of nonimmune Cactivation
in glomerular disease has led to the use of reagents to
identify glomerular bound C components, properdin
and related proteins, as well as to the search for
factors in the circulation capable of activating the C
cascade.
Immunofluorescence techniques. Immunofluores-
cence, the mainstay of immunopathologic diagnosis,
depends on the use of fluorochrome (fluorescein
isothiocyanate, tetramethyl rhodamineisothiocyanate,
etc.) labeled antibodies for detecting Ig and associated
phiogogenic proteins within renal biopsy specimens.
Anti-GBM antibodies react with antigens distributed
throughout the GBM and deposit evenly to produce a
smooth, linear pattern, while immune complexes de-
posit at random within the glomerular filter to produce
a granular or interrupted pattern. Experimental
studies indicate that about 5 ig of diffuse linear IgG
or 0.25 g of discrete granular antigen/g of renal tissue
can be detected by the immunofluorescence technique.
The deposits may be further characterized by the class
and subclass of immunoglobulin involved, and the
presence of various C components and fibrinogen-
related antigens (FRA) as well as nonglomerular
immune complex antigens. Immunofluorescence tech-
niques can also be utilized to identify cell types such as
thymus-dependent lymphocytes, so-called T cells,
within cellular infiltrates as seen, for example, in re-
jecting renal allografts [3].
Fluorescence is a property of a substance which,
upon exposure to an exciting light of a proper wave-
length, will emit a secondary light of a somewhat
longer wavelength. By inserting a barrier filter in the
optical path, the exciting light can be suppressed, allow-
ing viewing of the secondary light. Fluorescein, for
example, has a usable absorption maxima at 490 nm
and emits a secondary light at 517 nm. The intensity of
the light available for fluorescence study is dependent
upon the light source and the filter combinations
chosen. For maximal intensity the light is transmitted
to the tissue via an immersed cardioid dark field con-
denser utilizing as few reflecting surfaces as possible.
The recent introduction of vertical illuminators
utilizing dichroic mirrors with selective, reflective
properties has provided a useful alternate system, one
which provides good illumination, particularly at high
magnifications (the objective serving as its own con-
denser) [4l. Many investigators are enthusiastic about
this new system and its freedom from an immersed
dark field condenser; however, we do not feel that it
provides as intense illumination as the transmitted
systems (based on photographic exposure times). For
routine diagnostic evaluation, either means of illu-
mination is adequate.
High pressure mercury or xenon light sources pro-
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duce the greatest light intensities. Recently, halogen-
quartz light sources coupled with some of the inter-
ference filter systems have provided a much cheaper
(although weaker) source of illumination. This latter
system does not allow adequate utilization of other
filter systems which are helpful in differentiating
specific from nonspecific fluorescence. The recently
introduced interference filters, which transmit wave-
lengths rather selectively from around 490 to 500 nm
(optimal for fluorescein) or 546 nm (optimal for
rhodamine), have resulted in greater intensities of
fluorescence and greater ease in detection of anti-
bodies labeled with these fluorochromes, either in
tissue or on cell surfaces. Deposits scarcely visible with
older, commonly used filter combinations are often
quite bright when viewed with interference filters.
Indeed, in a recent comparative study, granular gb-
merular 1gM deposits were detected with interference
filters in 95% of mice compared to only 16 to 48% of
the same mice viewed with the older UG1 and BG12
exciter systems, respectively [5]. In our experience with
fluorescein interference filters over the past four years,
the differences have not been as striking as those found
in studies in the mice; however, the infrequent viewer
will be impressed with the light intensities produced by
these interference filter systems and the ease with
which deposits can be visualized. Because of the
relative sensitivities of the various filter combinations
used in routine renal immunofluorescence studies,
their notation is imperative for meaningful inter-
pretation of results.
No matter what fluorescence equipment and exper-
tise is available for this use, the final result will be only
as good as the reagents used and the quality of tissue
available. Florid immunoreactive deposits can often be
identified with less than optimal technique; however,
for detection of less obvious deposits, the greatest
care must be used. Heavy chain-specific antisera for
detecting Ig classes and subclasses, which lack light
chain reactivity, have largely replaced crude anti-
gammaglobulin sera used in early immunofluorescence
studies. Fluoresceinated anti-light chain sera are also
useful in studies of conditions such as amyloidosis, in
which glomerular and vascular deposits can some-
times be identified as being portions of an Ig light
chain [6]. Any absorptions necessary to render the
antiserum specific for the antigen in question should be
done with insolubilized antigen, in order to prevent
the inclusion of any soluble and potentially reactive
immune complexes in the final reagent. A reagent
which gives the greatest intensity of fluorescence with
the least background staining is necessary and can be
achieved most easily by utilizing fluoresceinated re-
agents which have undergone ion exchange chromatog-
raphy to select a population of antibody molecules
with an optimum fluorescein-to-protein ratio [7]. If
one wishes to utilize commercial reagents, a satisfac-
tory panel can be put together by screening a number of
reagents from several companies, with emphasis on
those purified by chromatographic techniques. Fluores-
ceinated-specific antibodies produced by elution from
immunoabsorbants may also be used [8]. The speci-
ficity of the reagents must always be shown at the level
of sensitivity of the immunofluorescence techniques
by absorption with the specific antigen. Blocking with
another unlabeled antibody of similar reactivity is also
helpful. Reliance on gel diffusion analysis (a relatively
insensitive technique) of the original antisera to deter-
mine specificity is foolhardy. Fluoresceinated antisera
specific for "nonimmunologic" serum proteins (al-
bumin, transferrin, etc.) should also be included in the
panel of reagents so that nonimmunologic entrapment
of serum proteins can be detected. Direct immuno-
fluorescence techniques have sufficient sensitivity for
routine renal studies, are simple to perform and require
fewer controls than the more cumbersome indirect
method.
Rapidly or "snap frozen" tissue (with liquid nitro-
gen) should be studied as soon as possible after
procurement and the thinnest possible microtome
sections obtained in a cryostat. Several different
fixation procedures for the sections can be used, and it
is important when a new technique is being tried that a
variety of fixation methods as well as unfixed tissue be
utilized to evaluate any untoward effects on the final
result. The stained sections should be viewed in a
standard way and attention paid to pattern and amount
rather than intensity of fluorescence (a function of the
reagent) of the deposit. The viewer should force him-
self to study all the structures in the section and not
merely concentrate on gbomeruli; tubular, interstitial
and vascular deposits may be equally important.
Serum proteins in tubular casts and in reabsorption
droplets in tubular epithelium from patients with
heavy proteinuria must be differentiated from immune
deposits. Autofluorescent cellular granules, connective
tissue and elastic lamina of vessels must not be con-
fused with specific immunofluorescent deposits. Atten-
tion should be paid to any unusual autofluorescent
material in the tissue; calcium deposits, for example,
may exhibit a striking autofluorescence. Adequate
specimens must be examined because presumed im-
nmue complex (granular) deposits may be quite
"focal" and involve only a few glomeruli in a bi-
opsy. We have occasionally seen biopsies with rather
striking granular deposits in three or four of 50
gbomeruli. On the other hand, granular deposits in
membranous gbomerulonephritis or linear deposits in
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anti-GBM antibody induced nephritis are usually very 
uniform from glomerulus to  glomerulus, so that a 
single glomerulus may be adequate for a tentative 
diagnosis. 
Anti-GBM nephritis. The hallmark of anti-GBM 
antibodies is linear deposits of Ig, usually IgG, along 
the GBM [2]. Prior to severe destruction of the 
glomerular architecture, the deposit is very smooth 
and continuous; however,with advancing damage, the 
GBM becomes compressed, corrugated and fragmented 
so that continuous smooth linear deposits are no 
longer to be found. With experience, however, one can 
usually have a high degree of suspicion of the pres- 
ence of anti-GBM antibodies even at late stages in the 
disease. The regular occurrence of focal or occasionally 
diffuse circumferential linear Ig deposits along the 
TBM is also extremely helpful in supporting a diag- 
nosis of anti-GBM nephritis [2]. Occasionally, no Ig 
may be detected in the glomeruli available for study in 
biopsy specimens of patients with advanced anti- 
GBM nephritis; however, subsequent elution 
studies will demonstrate the presence of anti-GBM 
antibodies and so point out the value of this latter 
technique. 
It is becoming increasingly clear that immuno- 
fluorescence detection of anti-GBM antibodies (linear 
staining) should be only the first step in making this 
diagnosis. Linear GBM deposits of Ig have been 
found in SLE [9] and often bright, but nonspecific 
(on elution), linear deposits of lg  (usually accom- 
panied by albumin) have been found in the kidneys of 
diabetics [lo], in about one-fourth of autopsy kidneys 
without renal disease, and not infrequently in kidneys 
after perfusion in preparation for transplantation [2]; 
all of which points out the necessity of corroborative 
elution studies or detection of circulating anti-GBM 
antibodies, or both, to support the diagnosis of anti- 
GBM nephritis. Certainly, the absolute necessity for a 
prerevascularization biopsy of a renal transplant for 
interpretation of any acute posttransplant Ig deposits is 
apparent. 
In addition to the above conditions which may have 
"nonspecific" linear deposits, a significant number 
(about 10%) of renal biopsy specimens have a faint 
linear "accentuation" of the GBM when stained for 
IgG. This finding occurs most often in kidneys with the 
least histologic abnormality, so that tissue for elution 
studies is usually not available. Such patients do not 
have circulating anti-GBM antibodies and we feel that 
the staining merely represents an unexplained but 
detectable increase in the 2% IgG normally present in 
the GBM [ll] .  This finding may help explain such 
observations as the recently reported 13% incidence 
of linear staining in patients with usually benign 
hematuria [12]. We would stress, however, that thesepa- 
tients be observed in an appropriate manner until the 
significance of this type of staining is better understood. 
The diagnosis of anti-GBM antibody-induced 
nephritis can be confirmed by demonstrating cir- 
culating anti-GBM antibodies. Indirect immunoflores- 
cence utilizing normal human or primate kidney 
tissue as a target has been the standard test for su& 
antibody determinations. This method detects anti- 
bodies in 87% of patients with anti-GBM antibody 
induced nephritis and pulmonary hemorrhage (Good- 
pasture's syndrome) and in about 60% of patients 
with anti-GBM antibody nephritis alone [2]. Hemag- 
glutination techniques, although probably more sensi- 
tive, have a troublesome background of as yet un- 
explained reactivity in patients without other evidence 
of anti-GBM antibody nephritis [13, 141. Gel diffusion 
is occasionally successful, but is the least sensitive of 
the methods available. The indirect immunofluores- 
cence assay is limited by the ready availability of 
normal kidney target tissue and variable degrees of 
reactivity between targets. It does have the advantage 
of detecting other reactivities in serum, such as anti- 
TBM antibodies, antirenal tubular brush border anti- 
bodies and antinuclear antibodies. 
We have recently extended our previous observa- 
tions on the use of a radioimmunoassay for anti-GBM 
antibodies in renal eluates [ l l ]  to detecting circulating 
anti-GBM antibodies. Other groups are also working in 
this area [15]. To date, studies have been done on 356 
patients with immunofluorescence characterization of 
their glomerular disease. The radioimmunoassay 
employs radiolabeled collagenase solubilized, and 
partially purified GBM, which is first reacted with the 
patient's serum. The mixture is then reacted with an 
anti-immunoglobulin antisera to precipitate the anti- 
body bound antigen (C.B. Wilson, H. Marquardt and 
F. J. Dixon, in preparation). Sera from 22 patients with 
Goodpasture's syndrome and linear glomerular 
immunoglubulin deposits were reactive in the anti- 
GBM radioimmunoassay, including sera from two 
patients who had been only questionably positive by 
indirect immunofluorescence. The radioimmunoassay 
was also positive in 12 of 20 nephritic patients with 
linear staining who had no pulmonary involvement. 
In three of these patients the reactivity had been un- 
detected by the indirect immunofluorescence assay. 
Neither assay was positive in the remaining eight 
patients, four of whom had elution-confirmed anti- 
GBM nephritis. With one exception, no diagnostic 
concentrations of circulating anti-GBM antibodies 
were found with either assay in 169 patients with 
granular (presumed immune complex) Ig deposits, 
including 13 with antinuclear antibodies. One patient 
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with granular immunoglobulin deposits had evidence 
of circulating anti-GBM antibodies by both radio- 
immunoassay and indirect immunofluorescence. This 
observation may be similar to that recently made by 
Klassen et a1 [16], on a patient who developed anti- 
GBM antibodies sometime after the onset of a classic 
immune complex type of membranous glomerulo- 
pathy. In addition, 19 nephritic patients with linear 
accentuation (IgG) of the GBM, 30 patients with 
glomerular C deposits alone and 96 patients with no 
immunofluorescent deposits failed to  react in the 
radioimmunoassay. 
The radioimmunoassay appears to be more sensi- 
tive than indirect immunofluorescence, being clearly 
positive in some cases when the latter is negative or 
equivocal. The reverse situation has not yet been 
observed. Direct comparison of the same positive 
serum sample shows that the radioimmunoassay is 
approximately four times more sensitive than immuno- 
fluorescence. The increased sensitivity should be help- 
ful when patients are followed serially to determine 
when the anti-GBM antibodies disappear in prepara- 
tion for transplantation. 
Previous studies using the indirect immunofluores- 
cence technique indicated that anti-GBM reactivity 
disappeared 3 to 25 months (mean, 8 months) after 
bilateral nephrectomy [2]. Too few observations of 
nonnephrectomized patients have been made to 
document whether nephrectomy is necessary for 
disappearance of circulating anti-GBM antibodies. 
While observations on autologous anti-GBM nephritis 
in sheep and early studies in man indicated that anti- 
GBM antibodies were more readily detected in 
nephrectomized subjects, further experience with 
patients, most of whom had advanced glomerular 
destruction, indicates that such kidneys have little 
immunoabsorptive capacity and circulating anti- 
GBM antibody concentrations are unaffected acutely 
by nephrectomy. 
The fact that, to date, no sera positive by indirect 
immunofluorescence have failed to react in the radio- 
immunoassay with collagenase-solubilized GBM 
suggests that the reactivity of such antibodies resides 
in the roughly 25% of the GBM composed of non- 
collagenous glycoproteins. This finding would confirm 
previous absorption studies which indicated that 
positive serum reactions with indirect immunofluores- 
cence technique could be absorbed with collagenase 
digested GBM [I 11. Preliminary studies utilizing radio- 
labeled cartilage collagen do suggest, however, that 
occasional sera have reactivity with the collagenous 
portion of the GBM as well. This may help to explain 
why others have thought the disaccharide moiety of 
collagen was the nephritogenic antigen. 
The radioimmunoassay has been automated and is 
now ready for large scale testing and screening of the 
nephritic population to determine the incidence of 
anti-GBM antibody-induced nephritis. 
Various techniques to  measure cellular sensitivity 
utilizing a patient's peripheral lymphocytes and GBM 
antigens may also be helpful in identifying immune 
responses to  the GBM [13, 14, 17, 181. There is little 
direct evidence, however, that sensitized cells play a 
role in the production of this form of glomerular 
injury, which can be readily produced by transferral of 
antibody alone. 
Immunofluorescence studies suggest that anti- 
GBM antibodies are responsible for the glomerular 
injury in about 5% of the renal samples submitted to 
our laboratory (Table 1). The predominant Ig in- 
volved is IgG, with IgA and IgM only infrequently 
being identified [2]. IgG subclasses have also been 
studied [19, 201. Fibrinogen-related antigen is often 
quite prominent in areas of crescent formation seen in 
the rapidly progressive form of the disease, but little 
FRA is usually present within glomerular capillary 
loops. Little is known about the events responsible for 
the induction of the anti-GBM response; however, a 
careful evaluation of toxic exposure [21] or viral infec- 
tion [22] is mandatory. Experimental demonstrations 
that endogenous basement membrane-like materials 
from the urine can induce "autoimmune" anti-GBM 
nephritis if properly presented suggest the possibility 
that the inciting event might also be endogenous. 
In patients with anti-GBM antibody-induced glo- 
merulonephritis and pulmonary hemorrhage (Good- 
pasture's syndrome) linear Ig deposits can often be 
identified binding to the alveolar basement membrane; 
in addition, antibodies capable of reacting with the 
GBM have been eluted from the lungs of these patients. 
These observations as well as the induction of anti- 
GBM antibodies with lung tissue in experimental 
animals suggest a common mediation mechanism. 
Patients with immune complex glomerulonephritis 
occasionally have pulmonary hemorrhage so that 
immunopathologic classification of Goodpasture's 
syndrome is mandatory [23,24]. Anti-GBM antibody- 
induced glomerulonephritis and pulmonary hemor- 
rhage may present with renal abnormalities, lung 
abnormalities or a combination of both [2]. There is 
little clear evidence about which organ system is 
primarily involved. It is well recognized that anti- 
GBM antibody-induced nephritis may occur without 
pulmonary disease. On the other hand, we have re- 
cently observed a patient with pulmonary infiltrates, 
hemoptysis and anemia who was diagnosed clinically 
as having idiopathic pulmonary hemosiderosis. This 
patient had linear deposits of IgG bound along the 
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alveolar basement membrane and evidence of cir-
culating anti-GBM antibodies. He has had no
clinical evidence of renal involvement, although a kid-
ney biopsy six months after his initial episode re-
vealed linear deposits of Ig along the GBM.
Immune complex nephritis. Granular deposits of Ig
usually accompanied by C are the hallmark of experi-
mental and spontaneous immune complex gb-
merulonephritis in animals as well as in an ever in-
creasing number of examples in humans (Table 2). It is
thought that most of the deposits originate as circu-
lating immune complexes; however, it is increasingly
apparent from experimental studies that glomerular
bound immune complexes are in dynamic equilibrium
with the circulation and antibody or antigen, or both,
can combine with or be dissociated from them. It is also
not unreasonable to suspect that Ig-Ig aggregates
(often cryoglobulins) and possibly C aggregates of
the proper configuration could lodge in glomeruli in
much the same way as we presume immune complexes
do. Since in situ formation of immune complexes is
thought to be involved in experimental thyroiditis in
mice and in renal tubular lesions of rabbits injected
with tubular antigens, a similar phenomenon might
occur in glomeruli as well. For example, recent experi-
mental studies have demonstrated clearly that anti-
body can react with material localized in the mesan-
gium [25].
Care must be exercised in examining human material
since granular deposition is often focal and may not
involve all glomeruli. It is also difficult to be certain of
the "specificity" of irregular or granular deposits of
Ig and C in gbomeruli that also have large amounts of
FRA. If localization of the immunoreacting deposition
conforms to that of the FRA, it is probable that serum
proteins are merely entrapped in the fibrin coagulum,
as suggested by the presence of albumin and other
"nonimmunologic" proteins.
Granular deposits of Ig usually accompanied by
complement are present in about one-half of the renal
biopsy specimens in our ongoing study (Table I). If
from this group are selected those patients thought on
historic and clinico-pathologic grounds to have
glomerulonephritis (many of whom are far advanced),
then the incidence of granular deposition increases to
between 70 and 80%. A generalized summary of the
type of deposits found in various clinico-pathologic
varieties of glomerulonephritis is presented in Table 3.
The pattern of deposition may be intense and general-
ized corresponding to the subepithelial dense deposits
visualized by electron microscopy in membranous
(or extramembranous) glomerulopathy, or scant and
involving only segments of the GBM or mesangium in
more focal glomerular lesions. Occasionally a patient
with fulminant glomerulonephritis may have little or no
detectable deposits within the glomeruli. Whether this
Table 2. Human immune complex glomerulonephritis
A. Immune complex glomerulonephritides in which antigen, specific antibody or both have been identified in
granular glomerular immunoglobulin deposits
Exogenous antigens
Foreign serum proteins, drugs
Streptococcal antigens
Staphylococcal antigens
Plasmodium malarial antigens
Enterococcus
Australia antigen
Oncornavirus-related antigen
Measles antigen
Systemic lupus erythematosus
Thyroiditis
Three cases of membranous giomerulonephritis in
Japan, sickle cell anemia
Colonic carcinoma
Cryoglobulinemia
B. Conditions with presumed immune complex glomerulonephritis (granular glomerular immunoglobulin
deposits) in which antigen-antibody systems should be identifiable
Drugs Penicillamine, gold, heroin, prophylactic inoculations
Infections Bacterial endocarditis, leprosy, syphilis, schisto-
somiasis, filariasis, infectious mononucleosis, van-
celia, Landry-Guiilain-Barré-Strohl syndrome
Neoplasia
Sarcoidosis
Serum sickness
Poststreptococcal glomerulonephritis
Infected venticuloatnial shunts
Quartan malarial nephrosis
Subacute bacterial endocarditis
Hepatitis
Lymphoma-leukemia
Subacute sclerosing panencephalitis
Endogenous antigens
Nuclear antigens
Thyroglobulin
Renal tubular antigens
Carcinoembryonic antigen
? Ig
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Table 3. A summary of glomerular Ig, C3 and ERA deposits in patients with glomerulonephritis (GN)
Glomerular immunofluorescence
A. Anti-GBM GN
Goodpasture's syndrome and rapidly pro-
gressive GN
B. Presumed immune complex GN
Proliferative GN, including poststreptococcal
Rapidly progressive GN
Membranous GN
Membranoproliferative GN
Focal GN, including mesangial hypertrophy
Focal sclerosis
Systemic lupus erythematosus
Henoch-Schonlein purpura
C. Lipoid nephrosis
Minimal change lesion
Linear igG, infrequent IgA, 1gM. C3, if present, usually
irregular. ERA prominent in crescents.
Scattered granular IgG. Variable presence of IgA and 1gM.
C3 usually present and may be observed in the absence of 1g.
ERA usually absent.
Granular IgG, variable IgA, 1gM. C3 usually present. ERA
prominent in crescents.
Generalized discrete granular IgG, C3, with variable IgA,
1gM. FRA usually absent.
Coarse peripheral C3 usually accompanied by IgG, and often
IgA and 1gM. ERA deposits variable.
Segmental granular and mesangial IgG, C3 often with pro-
minent mesangial IgA. 1gM and ERA variable.
Segmental granular IgG, 1gM, C3. IgA and ERA usually
absent
Prominent generalized or segmental granular and mesangial
IgG, IgA, 1gM and C3 deposits. FRA variable.
Prominent segmental and mesangial IgG, IgA, C3 and ERA.
1gM variable.
No IgG, IgA, 1gM, C3, ERA deposits.
a Useful references: 2, 26—33, 67, 69, 86—91. GBM, glomerular basement membrane; FRA, fibrinogen-related
antigens
represents a loss of previously deposited material due
to the intensity of the inflammatory response, or
another as yet unidentified mechanism of glomerular
injury, is unknown. Kidneys thought to represent end
stages of glomerulonephritis may be free of Ig deposits
or if the deposits are present they may be limited to the
least damaged glomeruli. The few serial studies avail-
able suggest that Ig deposits may disappear as
glomerular damage advances, while C deposits may
remain or even intensify. It is of great interest that, in
our experience, roughly l0% of nephritic kidneys have
granular deposits of C alone (Table 1). The possible
significance of this finding will be discussed later.
In addition to the distribution of the deposits, the
class or subclass of Ig may be identified by using
monospecific antisera. For example, glomerular IgE
deposits were recently reported in patients with lipoid
nephrosis; however, the finding has not been sub-
sequently confirmed [26, 27]. Granular mesangial
deposits of IgA, as the predominant immunoglobulin,
have been identified in Henoch-Schonlein purpura
[28, 29], as well as in patients with recurrent and often
benign hematuria [30—32]. Although the IgA deposits
usually contain IgG and C (and involve the GBM as
well in Henoch-Schonlein purpura), their pre-
dominance and localization has generated great in-
terest. The granular nature of the deposits would
suggest their origin as immune complexes and their
localization predominantly in the mesangium would
suggest that they were relatively large and insoluble,
thus leading to a mesangial localization and relatively
benign clinical pathology. Binding of IgA to bacterial
products lodged in the mesangium could also be
considered and should be determined. Granular IgA
GBM deposits may also be diffuse and are frequently
present in patients with SLE [33].
Based on findings in animals (serum sickness, viral
infections, etc.) and on an ever increasing number of
human examples (Table 2) most, if not all, kidneys
containing granular deposits of Ig are presumed to
have immune complex deposits. It goes without saying
that intensified efforts must be made to identify the
antigen-antibody systems in each patient. If sufficient
tissue is available, the immune complexes may be
removed for study by elution in buffers known to
dissociate antigen-antibody bonds. The eluted mate-
rials can then be studied by a variety of immunologic
and physical chemical techniques in order to define
the nature of the antigen and the antibody specificity.
In experimental serum sickness in which radiolabeled
antigen or antibody is used, it is possible to easily elute
about 70% of the bound immune complex material;
however, if no attempt is made to separate the antigen
and antibody while still dissociated, upon return to
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physiological conditions they will recombine (7O%)
and probably be lost to further study. Since the antigen
is usually unknown, multiple methods may need to be
tried before a satisfactory separation is accomplished.
In addition to separating the antigen and antibody,
destruction of the antigen (or antibody), as in the case
of DNA with DNAase, would also reduce recombina-
tion.
If only biopsy specimens are available, immune-
complexed antigen may be sought using immuno-
fluorescence. Since antibody from the circulation may
have covered the antigenic portion of the immune
complex, partial elution may be required to uncover
sufficient antigenic sites for detection with the fluores-
ceinated antiserum. Glomerular immune-complexed
antibody may be similarly sought using fluoresceinated
or radiolabeled antigen.
Detection of similar antigen-antibody complexes in
the circulation would establish their nonrenal origin
and has been undertaken successfully in animals with
serum sickness and viral nephritis, as well as being
suggested by serial fluctuations of circulating DNA
and anti-DNA in humans with SLE. Cryoglobulins in
patients with nephritis may also be a relatively easily
isolated serum fraction in which to detect immune
complexes. Sensitive and clinically applicable methods
of detecting circulating immune complexes have been
slow in coming. Sera with decreased complement con-
centrations or anticomplementary activity should be
suspect. Analytical and sucrose density ultracentri-
fugation, gel filtration and Clq and monoclonal rheu-
matoid factor precipitation are of varying sensitivity
and reactivity, and serve primarily as research tools.
Platelet aggregation, although perhaps more sensitive,
is plagued by nonreproducible platelet preparations.
Two methods under current investigation, complement
consumption utilizing minute and limiting quantities of
complement [34] and binding of complexes to either Tg
or C receptors on cultured lymphocytes, show promise
[35]. If such techniques were to be successful, they
would play as prominent a role in diagnosis of neph-
ntis as does detection of anti-GBM antibodies. They
would also be helpful in determining optimum timing
for renal transplantation in an attempt to avoid recur-
rent immune complex glomerulonephritis,
The patient's physician must serve as a detective,
narrowing the field of potential antigen-antibody
systems which could act either singly or in combination
to produce the numerous, as yet "idiopathic," forms
of glomerulonephritis with granular glomerular Ig
deposits (presumed immune complexes). A careful
history and clinical evaluation should cover possible
antigen exposure, including drugs and inoculation;
associated microbial infections, including persistent
viral infections, such as hepatitis; renal trauma and
vascular insult or toxic exposure; neoplasia; and
associated autoimmune responses, such as thyroiditis
or SLE. Since chronic viral infections are nearly
universally associated with immune complex gb-
merulonephritis in animals, viral infections would be
suspect in man as well. Attempts to measure circulating
antiviral antibody responses have not resulted in
detection of common agents; however, isolated and
unexplained elevations in antibody response have
been seen, especially in patients with SLE [36].
Attempts to isolate viral agents from renal biopsy
tissue have been disappointing [37] and, even if
successful, the isolate would be difficult to relate to
immune complexes. Virus-like particles in endothelial
cells so common in SLE are now being found with
increasing frequency in other conditions [38] and may
only reflect degenerative changes within the cell. If
circulating antigen and antibody were present m
nearly equivalent proportions, they would combine
and neither would be detectable by the usual immuno-
logic techniques, a common situation in viral nephritis
in animals. It may then be profitable to utilize other
measures of immunity, such as cellular sensitivity, to
detect otherwise "masked" antibody responses as a
lead to antigen-antibody systems involved in a partic-
ular case. Table 2 lists a number of presumed im-
mune complex glomerulonephritides in which antigen
identification should be relatively easy. Also included
are conditions such as sarcoidosis and neoplasia in
which antigen identification could result in an under-
standing of the etiology of these otherwise obscure
conditions.
Immune complexes may induce arterial as well as
glomerular injury as, for example, in SLE. Hepatitis
SH antigen-antibody complexes have been found in
vascular lesions of some polyarteritis patients [39, 40]
and may produce glomerulonephritis as well [41].
Tmmunofluorescence studies of glomeruli of patients
with Wegener's granulomatosis [42] and some patients
with scleroderma [43] suggest that immune complexes
may be implicated in these conditions as well. Vascular
deposits of Ig, C and FRA have been found in patients
with malignant hypertension ([44, 45], C. B. Wilson,
unpublished observations), it is not known if such
deposits have immunologic specificity or are merely
trapped in areas of inflammation; findings of elution
studies would be of particular interest. Absence of ig
and C in renal problems associated with consumptive
coagulopathy in which FRA are prominent, such as
the hemolytic uremic syndrome [46, 47], suggests that
immune reactions of the types here discussed are
probably not involved. Likewise, immunopathologic
studies of the pathogenesis of familial nephropathy
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have not shown that either anti-GBM antibodies or
immune complexes are involved [48, 49]. Mauer and
associates have recently observed that Ig and C
deposits accumulate in glomeruli of rats with experi-
mental diabetes mellitus [50, 51]. These findings
should renew interest in immunopathologic studies
of the renal involvement found with this disease in
man.
Complement and glomerular disease. Depressions in
serum C have been used to implicate immune proc-
esses in the production of glomerular disease. Indeed,
hemolytic C (CH5O) is often depressed in acute
poststreptococcal glomerulonephritis and SLE; how-
ever, in many other presumed immune complex types
of glomerulonephritis, as well as in anti-GBM anti-
body induced nephritis, serum C concentrations are
often normal [52]. The recent recognition of alternate
C activation, beginning at C3 and bypassing the
classical C1-4-2 reaction, has emphasized the need to
detect both early and late acting C components in the
serum [53, 54]. The alternate pathway, which involves
the interaction of an as yet incompletely defined series
of proteins, including properdin [55], C3 proactivator
[56, 57] and the C3b fragment of C3 [58, 59], may be
activated by immunoglobulin, including IgA and
nonimmune means with bacterial lipopolysaccharides,
yeast (zymosan) and particulate inulin. Factors are
present in the sera of some hypocomplementemic
patients which can activate this pathway [60]. Such
factors are detectable by observing their ability to
activate C3 in normal serum (detected by changes in
electrophoretic mobility) or to lyse glutathione
sensitized red blood cells (C. M. Arroyave, E. H.
Vallota, and H. J. Müller-Eberhard, in preparation).
This so called C3 nephritic factor(s) which persists after
nephrectomy is now thought to be an activated nor-
mal constituent of the initial stages of the alternate
pathway, reacting before properdin [61]. C3 depression
without concomitant depression of initial C compo-
nents (Cl, C4, C2) [62], as well as decreased properdin
[63] and C3 proactivator [64] concentrations, suggest
utilization of the alternate pathway and is typical of
childhood hypocomplementemic glomerulonephritis
and, to a lesser extent, acute poststreptococcal gb-
merulonephritis. Utilization of the entire C sequence
in addition to properdin is seen in SLE and indicates
classical C activation with possible additional alter-
nate C pathway activation.
The serum observations can be extended to im-
munofluorescence detection of C components in
gbomeruli. The presumed immune complex glomeru-
lonephritides, as identified by granular Ig deposits, are
almost always associated with granular C deposits [65].
Both initial and late acting components are usually
present, indicating classical activation has occurred.
In anti-GBM antibody nephritis, C deposits are found
in 65 to 75% of patients; and in many of these patients
the deposits are less striking than the Ig deposits and
are usually interrupted and irregular rather than
linear. When C3 is present, both early and late
acting C components can usually be identified. In
one-third to one-fourth of patients who have few or
no C deposits, other as yet unidentified pathways must
be responsible for the antibody-induced injury. No
obvious differences in the severity of the clinical
courses of patients with anti-GBM nephritis have been
related to the presence or absence of C deposits in the
few patients thus observed [651.
In about l0% of renal tissue studied (usually from
patients in advanced stages of glomerular injury), C3
(Table 1) and later acting C components may be pre-
sent in the absence of Ig and initial C components [65].
Properdin may also be detected [66]. Similar findings
have been observed in childhood hypocomplemente-
mic glomerulonephritis, but even then the majority of
patients have Ig and initial C components sometime
during the course of their disease [67]. Little is known
about the relative disappearance rates of Ig and C
from glomerulonephritic kidneys, but limited serial
observations suggest that C may persist or even in-
crease while Ig becomes undetectable. Indeed, we have
observed kidneys in which Ig and both initial and late
C components are present in a minority of glomeruli,
while only intense C3 and later C components are
found in the majority of glomeruli [65]. This suggests a
transition in pathogenesis is occurring, with perpetua-
tion of a preceding immune complex-induced gb-
merular injury through an as yet unexplained continu-
ing C deposition possibly utilizing the alternate C
pathway.
Tubular and interstitial injury. Interest is beginning
to focus on immune processes which may produce
tubular and interstitial injury, either associated with
glomerulonephritis or occurring as a primary disease
[68, 69]. Seventy percent of patients with anti-GBM
antibody-induced nephritis have evidence of anti-
TBM antibodies as well. The reactivity of the anti-
TBM antibodies is usually restricted to a portion of the
tubules, but occasionally may be more generalized.
Infrequently, anti-TBM antibodies without associated
anti-GBM reactivity can be identified in allografted
kidneys [70] and in association with methicillin
toxicity (W. A. Border, D. H. Lehman, J. D. Egan
and C. B. Wilson, in preparation).
Granular deposits of Ig and C which suggest im-
mune complexes are found in the TBM, peritubular
capillaries and/or interstitium of almost 75% of SLE
kidneys. Similar extragbomerular deposits are in-
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frequent in other immune complex glomerulone-
phritides (D. H. Lehman and C. B. Wilson, in pre-
paration). Many kidneys, occasionally essentially
normal ones, have tubular and vascular deposits of C3
in the absence of 1g.
Granular immunoglobulin deposits in and about
the TBM, peritubular capillaries and in the inter-
stitium are presumed to represent immune complex
deposits. In experimental serum sickness it has been
possible to demonstrate antibody, antigen and C in
similar locations, indicating that they are probably
combined as immune complexes. Granular deposits of
unknown origin and significance are also observed in
renal tubular cells, and are often associated with the
TBM in rabbits immunized with renal tubular antigens.
Electron microscopic localization of these deposits
between the renal tubular plasma membrane and the
TBM suggests that they may represent in situ formed
immune complexes, similar to those seen in experi-
mental and clinical thyroiditis.
Immunopathologic studies of renal transplants. im-
mune injury to renal transplants may occur acutely
within minutes of transplantation or over prolonged
periods of time [71]. Hyperacute rejection is induced
by preformed antibodies which can sometimes be
demonstrated by immunofluorescence as being dif-
fusely bound to the vascular endothelium [72]. Tissue
injury is mediated at least in part by polymorphonu-
clear leukocytes and coagulation, with FRA de-
positing heavily in glomeruli and vessels. The amount
of fibrin present often makes it difficult to be certain
that accompanying Ig and C deposits have immuno-
logic specificity, since they may merely be trapped
within a fibrin coagulum. Quantities of antibody
sufficient to induce hyperacute rejection may also
never reach the concentration necessary for immuno-
fluorescence detection.
The same immunopathologic techniques utilized to
identify the immune processes responsible for primary
disease are applicable to the study of more chronic
immune injury in renal transplants. interpretation of
the findings is complicated by the multiple events which
may take place simultaneously in the transplant.
First, the transplanted kidney is subjected to the same
immune processes which were responsible for the
patient's original renal disease. Second, allografts are
exposed to varied immune responses generated by the
rejection process. Also, the allograft can potentially
induce immune responses to renal constituents not
usually histoincompatible, such as basement mem-
branes and renal tubular antigens, thus stimulating
production of potentially nephrotoxic anti-basement
membrane antibodies and circulating immune com-
plexes. Third, administration of various immuno-
suppressive regimens, including foreign serum pro-
teins in the form of antilymphocyte sera, almost surely
modifies the contributions of the other two major
factors.
Recurrence of glomerulonephritis in renal trans-
plants has been clearly shown in transplants in rats
with autologous immune complex glomerulonephritis
[73] and in unmodified renal transplants from identical
human twins [74]. in this latter instance, glomerulone-
phritis recurred in 11 of 18 patients within six years of
transplantation, while similar lesions were not obser-
ved in nonglomerulonephritic patients in the same
series. Anti-GBM antibodies can also cause recurrent
glomerulonephritis, particularly when they are present
in the circulation at time of transplantation [2, 75, 76].
immunofluorescence and elution studies can confirm
the presence of anti-GBM antibodies in the transplant.
To complicate matters, anti-GBM (C. B. Wilson,
unpublished observations) and anti-TBM antibodies
[70] related to immunologic stimuli from the grafts
may develop in transplanted patients. Adequate pre-
and posttransplant studies are required to document
recurrence of anti-GBM nephritis.
Clinical, morphologic and/or irnmunofluorc cence
studies strongly suggest recurrence of "IgA-lgG
nephritis" [30], idiopathic iiephrotic syndrome [77],
dense deposit disease [78] and hypocomplementemic
glomerulonephritis [79] in renal transplant patients.
That immune complex-induced glomerular injury can
recur in transplants (as demonstrated by immuno-
fluorescence and morphologic observations) can
scarcely be doubted; however, a true recurrence can-
not be confirmed until identical antigen-antibody
systems can be identified in both the native and trans-
planted kidneys. induction of autologous immune
complex nephritis by implantation of unvascularized
kidneys in the peritoneal cavity of rats [80] and induc-
tion of nephritis in graft vs. host reactions in which H2
antigens may be involved in immune complex forma-
tion [81] indicates that antigens within a renal trans-
plant are potentially capable of inducing immune
complex nephritis. Only when techniques are devel-
oped to detect the antigenic component of immune
complexes will these complicated problems be solved.
Renal allografts that are rejected within the first
few days may have few or no detectable ig or C
glomerular deposits, and vascular deposits of 1g.
particularly igM, C and FRA vary. Long-term
renal allografts frequently have irregular glomerular
deposits of ig and C deposits often similar to those seen
in patients with immune complex glomerulonephritis
[82---84]. Vascular deposits of ig and C are also
frequent. Since similar deposits are occasionally
observed in patients without previous glomerulone-
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phritis, it is apparent that, in some instances, these
deposits are related to immune processes directed
against the graft rather than to recurrence of a
nephritic process. In our experience, Ig and C de-
posits in glomeruli of transplants are most frequent in
patients with a previous glomerulonephritis. These
observations are similar to those made in identical
twins. When glomerular deposits do occur in non-
nephritic transplanted patients, their occurrence seems
to be related in part to the degree of histoincompati-
bility (as currently detected) between the graft and the
recipient, with patients thought to have HLA-identical
matches having fewer deposits. Only greatly expanded
pre- and posttransplant studies and advances in im-
mune complex antigen identification can determine
the relative frequencies of recurrent nephritis and
rejection-related immune injury. The potential develop-
ment of serum sickness and antibasement membrane
nephritis [85] must also be kept in mind when trans-
plant recipients are receiving antilymphocyte globulin
preparations.
Conclusions. The mechanisms and diagnostic fea-
tures of immunologic renal damage have been out-
lined. Identification of the nephritogenic GBM
antigen(s) and the events responsible for induction of
the "autoimmune" anti-GBM response are being
studied. Many investigators are searching for the
antigen-antibody systems which could be responsible
for the many presumed immune complex human
glomerulonephritides identified now only by their
granular glornerular Ig and C deposits. To aid in this
search, physicians, by being alert to potential immune
responses in individual patients, can narrow the almost
limitless antigenic possibilities to a few testable
systems. The existence of alternate and possibly non-
immune complement activation suggests a possible
additional mechanism of glomerular injury. It is also
becoming increasingly clear that immune mechanisms
similar to those producing glomerular injury may be
involved in tubular and interstitial injury; this points
out the need for correlative immunopathologic,
structural and functional studies of tubules.
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